GeneDx Holdings Corp. WGS
- Market cap
- $2.6B
- P/E
- 0.0×
Follow WGS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 318.78 | 140.58 | 7.26 | 1.16 | 2.47 | 55.17 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 404.25 | 896.94 | 154.11 | 17.92 | 89.11 | 170.87 |
High Price
|
|||
| — | — | — | — | — | 1,200 | 1,100 | 1,000 | 1,000 | 1,300 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 196 | 179 | 212 | 235 | 203 | 305 | 428 |
Revenue
|
|||
| — | — | — | 42.20% | 2.25% | (7.82%) | (11.40%) | 44.43% | 63.64% | 69.74% |
Gross Margin
|
|||
| — | — | — | (30) | (241) | (245) | (598) | (177) | (53) | (21) |
EBT
|
|||
| — | — | — | (15.14%) | (134.58%) | (115.64%) | (254.81%) | (87.23%) | (17.23%) | (4.94%) |
EBT Margin
|
|||
| — | 0 | — | (30) | (241) | (245) | (549) | (176) | (52) | (21) |
Net Income
|
|||
| — | — | — | 6 | 12 | 22 | 59 | 34 | 22 | 25 |
Depreciation
|
|||
| — | — | — | 0.00 | 896,610.00 | 64.80 | 22.93 | 8.33 | 11.36 | 14.93 |
Revenue/Sh
|
|||
| — | — | — | (7,905,874.00) | (0.14) | (74.92) | (53.79) | (7.23) | (1.94) | (0.73) |
Earnings/Sh
|
|||
| — | — | — | 0.00 | (465,640.00) | (58.15) | (31.18) | (7.41) | (1.06) | 1.16 |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (159,870.00) | (6.35) | (1.40) | (0.07) | (0.20) | (0.66) |
Capex/Sh
|
|||
| — | — | — | 0.00 | (625,510.00) | (64.50) | (32.58) | (7.48) | (1.26) | 0.50 |
Free CF/Sh
|
|||
| — | — | — | 0.00 | 21,940.00 | 118.52 | 24.78 | 9.38 | 9.12 | 10.76 |
Book Value/Sh
|
|||
| — | — | — | 0 | 0 | 3 | 10 | 24 | 27 | 29 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 2.27 | 0.40 | 0.32 | 6.77 | 8.71 |
PS Ratio
|
|||
| — | — | — | 0.00 | 47.05 | 1.24 | 0.37 | 0.28 | 8.43 | 12.09 |
PB Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 0.44 | (0.10) | (0.07) | 6.47 | 8.43 |
EV/Sales
|
|||
| — | — | — | 0.00 | 0.00 | (0.44) | 0.07 | 0.07 | (58.19) | 252.56 |
EV/FCF
|
|||
| — | — | — | (19) | (93) | (190) | (319) | (180) | (28) | 33 |
Op' Cash Flow
|
|||
| — | — | — | (15) | (32) | (21) | (14) | (2) | (5) | (19) |
Capex
|
|||
| — | — | — | (34) | (125) | (211) | (333) | (182) | (34) | 14 |
FCF
|
|||
| — | — | — | — | 101 | 382 | 68 | 124 | 143 | 159 |
Working Cap'
|
|||
| — | — | — | — | 40 | 11 | 6 | 53 | 52 | 48 |
Total Debt
|
|||
| — | — | — | — | (68) | (390) | (118) | (77) | (89) | (123) |
Net Debt
|
|||
| — | — | — | 0 | 4 | 388 | 254 | 228 | 245 | 308 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (191.81%) | (60.91%) | (105.06%) | (38.64%) | (12.48%) | (4.46%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | (306.78%) | (74.97%) | (9.30%) | (4.42%) |
ROIC
|
|||
| — | — | — | 0.00% | (831.46%) | (845.41%) | (171.07%) | (72.97%) | (22.10%) | (7.60%) |
ROE
|
|||
GeneDx Holdings Corp. peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NEO NeoGenomics, Inc. | $2.5B | 0.0× | Compare |
| CDNA CareDx, Inc. | $3.2B | 29.6× | Compare |
| PSNL Personalis, Inc. | $1.8B | 0.0× | Compare |
| VCYT Veracyte, Inc. | $3.9B | 31.5× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ADPT Adaptive Biotechnologies Corporation | $4.7B | 0.0× | Compare |
| SHC Sotera Health Company | $5.3B | 32.1× | Compare |
| GRAL GRAIL, Inc. | $5.5B | 0.0× | Compare |
| OPK OPKO Health, Inc. | $1.2B | 0.0× | Compare |
GeneDx Holdings Corp. (WGS) key facts
- GeneDx Holdings Corp. (WGS) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- As of September 25, 2026, WGS traded at $88.40, a market capitalization of $2.6 billion.
- Return on equity was −7.60% and debt-to-equity 0.40.
GeneDx Holdings Corp. (WGS) Latest News
24 Sep
GeneDx (WGS) Q2 revenue $114.4M, up 11% YoY; exome/genome revenue $100.3M and volume 30,785 tests, +32%. Record testing volume; gross margin 70% (up from 69%). Adjusted net income $0.4M, an $8.6M QoQ improvement; profitability returned a quarter early. Full-year revenue guidance remains $475–$490M. CEO Katherine Stueland says the company is underearning relative to potential and fixing that is the top priority. Reimbursement timing remains key: blended per-test rate $3,258, roughly flat QoQ, but Carelon expansion boosted coverage from 47% to 87% for ~56M lives; cash collection lags, with benefits due in Q4 2026 and mostly in 2027. New pediatric channels delivered strongest growth. Valuation model projects $137 by end-2028 (~61% total return, ~23% annualized) with 19.4% revenue growth, 6.4% margins, 83.3x exit P/E. Low/Med/High scenarios imply substantial upside through 2030. Expanded payer coverage and reimbursement timing are expected to materially improve cash flow and profitability, driving meaningful upside.
9 Sep
GeneDx and Beren Therapeutics launch NPC GenomeComplete to improve diagnosis of Niemann-Pick Disease Type C. Product launch expands GeneDx diagnostic capabilities in rare diseases.
24 Aug
GeneDx study supports hospital-wide adoption of rapid genomic sequencing at Seattle Children’s Hospital. Endorsement for broad hospital adoption of rapid sequencing expands GeneDx clinical reach and revenue potential.
19 Aug
GeneDx Holdings Corp. (WGS) stock may advance if earnings estimates continue rising. Rising earnings estimates can lift investor sentiment and valuation for GeneDx Holdings.
11 Aug
GeneDx launches online offering to enhance accessibility of exome testing for children with global developmental delay, intellectual disability and epilepsy. New online testing service may expand customer reach and support modest revenue growth but does not transform core operations or market position.
10 Aug
GeneDx Holdings Corp. (WGS) held its Q2 2026 earnings call, covering financial results, operational updates, and forward-looking guidance for the genetic testing company. Quarterly earnings calls deliver core financial data and strategic outlook that directly shape investor views and company valuation.
7 Aug
GeneDx Holdings (WGS) stock rose 18.4% after reaffirming its 2026 outlook and raising equity from Blackstone. Reaffirmed 2026 outlook plus Blackstone equity infusion supplies capital and signals credible growth path.
4 Aug
GeneDx Holdings Corp reported record volume during its Q2 2026 earnings call along with early growth indicators. Record volume achievement in earnings call points to major operational gains that can shift company trajectory and investor views.
GeneDx Holdings Corp. released its Q2 2026 earnings call summary covering quarterly financial results, operational updates, and forward-looking guidance. Quarterly earnings details typically influence near-term stock sentiment and valuation without altering long-term company fundamentals.
3 Aug
GeneDx Holdings Corp. (WGS) released Q2 earnings call highlights covering financial results and operational updates. Q2 earnings and guidance directly shape investor views and near-term stock movement.
GeneDx Holdings Corp. (WGS) Q2 earnings and revenues beat analyst estimates. Q2 earnings and revenue beat signals stronger financial results likely to lift near-term market sentiment and stock performance.
GeneDx Holdings Corp. (WGS) released its second quarter 2026 financial results. Quarterly earnings releases update financial performance and may shift near-term investor views without altering long-term strategy.
21 Jul
GeneDx Holdings Corp. (WGS) stock declined after revenue fell short of expectations. Revenue shortfall triggered immediate stock decline with moderate effects on near-term performance and sentiment.
17 Jul
GeneDx Holdings Corp. (WGS) shares declined after the company substantially reduced its 2026 financial guidance. Significant 2026 guidance cut directly triggered stock decline and signals major negative shift in future trajectory.
16 Jun
GeneDx names Mark Gardner President to lead next phase of scale and growth. New president appointment targets scaling and growth execution.
6 Jun
GeneDx Holdings missed Q1 2026 earnings, cut guidance, and faces legal scrutiny, pressuring valuation and stock outlook. Missed earnings, reduced guidance and legal scrutiny together create major negative pressure on financial results and investor sentiment.
23 May
Healthcare investor added $43 million stake in GeneDx Holdings Corp. (WGS). Company reports 34% volume growth as genomics leader. Fresh capital infusion and volume growth may lift near-term sentiment without altering core trajectory.
16 May
GeneDx Holdings missed earnings expectations, cut its guidance, and faces a securities investigation, prompting valuation reassessment amid weakened outlook and investor scrutiny. Earnings miss, guidance cut, and securities investigation together signal major negative pressure on future results and market perception.
5 May
GeneDx Holdings Corp. (WGS) stock is plummeting today due to unspecified negative developments. Sharp stock decline signals major hit to investor sentiment and near-term market performance.
GeneDx Holdings Corp. (WGS) stock plummeted 45% after the release of alarming results. A 45% stock plunge from alarming results signals major setbacks likely to alter investor sentiment and company trajectory.
GeneDx Holdings Corp. (WGS) cut its financial guidance and shifted its core business focus, prompting debate on whether these moves undermine the bullish investment case for the stock. Guidance cut signals weaker financial outlook while core shift indicates major strategic pivot with potential to reshape competitive positioning and investor sentiment.
4 May
GeneDx Holdings Corp. (WGS) released Q1 2026 earnings call summary detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings call summary discloses financial performance and guidance that significantly influence stock trajectory and investor sentiment.
GeneDx Holdings Corp. (WGS) released Q1 earnings call highlights detailing financial performance, revenue growth, and future outlook. Q1 earnings highlights disclose key financial metrics and strategic updates that significantly shape investor expectations and stock trajectory.
GeneDx Holdings Corp. (WGS) released Q1 2026 earnings call transcript detailing financial results, revenue growth, and future guidance. Q1 2026 earnings transcript provides key financial metrics, operational updates, and forward-looking statements directly influencing investor sentiment and stock performance.
GeneDx Holdings Corp. (WGS) reported first quarter 2026 financial results and updated its full-year outlook. Quarterly financial results and full-year outlook updates significantly affect stock performance and investor sentiment.
GeneDx Holdings Corp. (WGS) Q1 2025 earnings call transcript details quarterly financial results, revenue growth, diagnostic volume increases, profitability improvements, and optimistic full-year guidance. Q1 2025 earnings show strong revenue growth, margin expansion, and raised guidance signaling major positive shift in trajectory and investor sentiment.
GeneDx Holdings Corp. (WGS) released Q2 2025 earnings call transcript detailing financial results, revenue growth, and future guidance. Q2 2025 earnings transcript reveals financial performance, strategic updates, and outlook directly influencing stock trajectory and investor sentiment.
GeneDx Holdings Corp. (WGS) reported a first-quarter loss and revenue below estimates. Q1 loss and missed revenue estimates indicate weaker financial results, moderately affecting investor sentiment and short-term performance.
27 Apr
GeneDx Holdings Corp. (WGS) anticipates robust revenues from exome and genome sequencing to potentially boost its Q1 earnings amid expectations of strong performance in these core areas. Expected revenue strength in exome and genome sequencing could moderately enhance Q1 financial results and market sentiment.
31 Mar
Cathie Wood bought $3.1 million worth of GeneDx Holdings Corp. (WGS) shares, a genomics company backed by Nvidia. Cathie Wood's $3.1 million purchase signals investor confidence in GeneDx's Nvidia-backed genomics tech, likely boosting short-term market sentiment.